Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Review of the safety and efficacy of ustekinumab.

TitleReview of the safety and efficacy of ustekinumab.
Publication TypeJournal Article
Year of Publication2010
AuthorsScherl EJ, Kumar S, Warren RU
JournalTherap Adv Gastroenterol
Volume3
Issue5
Pagination321-8
Date Published2010 Sep
ISSN1756-2848
Abstract

Ustekinumab is a subcutaneously and intravenously administered fully human monoclonal immunoglobulin (IgG1) antibody targeting the interleukin (IL)-12/23 shared P40 subunit. The pivotal role of IL-12/23 inflammatory-mediated pathways is increasingly recognized in a plethora of immune-mediated inflammatory disorders including Crohn's disease, psoriasis, and multiple sclerosis. In a randomized controlled trial of ustekinumab in moderate-to-severe Crohn's disease, clinical response was achieved most notably in infliximab-experienced primary and secondary nonresponders and suboptimal responders.

DOI10.1177/1756283X10374216
Alternate JournalTherap Adv Gastroenterol
PubMed ID21180612
PubMed Central IDPMC3002587